Last updated: March 18, 2026
What is NDC 70792-0812?
NDC 70792-0812 corresponds to Ado-trastuzumab emtansine (Kadcyla), a targeted therapy used primarily for HER2-positive breast cancer. It is an antibody-drug conjugate (ADC) combining trastuzumab with the cytotoxic agent emtansine.
Market Overview
Indications and Market Penetration
- Approved Uses:
Initially approved in 2013 for metastatic HER2-positive breast cancer following prior trastuzumab-based therapy. Subsequent approvals include adjuvant settings and metastatic gastric cancer.
- Market Size:
Estimated global breast cancer treatment market valued at approximately USD 20 billion as of 2022, with HER2-positive subset representing roughly 30%. Kadcyla's share within this is driven by clinical use and approval scope.
- Competitive Landscape:
Competing therapies include trastuzumab (Herceptin), pertuzumab (Perjeta), and newer ADCs like trastuzumab deruxtecan (Enhertu). The ADC segment's growth is robust, driven by advancements in targeted therapy.
Sales Data
- 2022 Revenue:
Approximately USD 2.2 billion globally, per IQVIA data.
- Growth Trends:
Steady to increasing, with a CAGR of about 8% over five years, influenced by expanded indications and increasing adoption in early-stage treatment.
Manufacturing and Supply Considerations
- High manufacturing complexity due to ADC technology.
- Supply chain disruptions mildly impact pricing and availability.
Price Analysis
Current Pricing
- List Price:
Approximately USD 11,600 per 100 mg vial, translating to about USD 116,000 per treatment cycle for typical dosing regimens.
- Reimbursement & Pricing:
Insurance reimbursements approximate USD 80,000 to USD 100,000 per cycle, considering discounts and negotiations.
Pricing Dynamics
- Comparison with Similar ADCs:
Trastuzumab deruxtecan (Enhertu) lists around USD 18,000 per 100 mg vial, higher than Kadcyla, but with different indications and efficacy profiles.
- Price Evolution:
Slight declines in net prices observed due to market competition and biosimilar development.
Cost Drivers
- Complexity of manufacturing ADCs impacts cost of goods sold.
- Patent protections provide temporary pricing power; patent expiry could influence prices over the next 5-8 years.
- Reimbursement strategies vary by country, affecting net market prices.
Future Price Projections
Factors Influencing Future Pricing
- Patent Lifecycle:
Patent protection is scheduled to expire around 2028-2029, likely leading to biosimilar competition.
- Market Expansion:
Growing indication approval in earlier disease stages can increase administered volume, impacting price strategies.
- Competitive Pressure:
Introduction of biosimilars or next-generation ADCs may lower prices.
- Regulatory & Policy Environment:
Rising focus on value-based pricing and price negotiations could reduce margins.
Projected Price Trends (2023-2030)
| Year |
Estimated Average Price per Treatment Cycle |
Key Influences |
| 2023 |
USD 100,000 |
Stable, with slight downward pressure from negotiations |
| 2025 |
USD 90,000 |
Increased biosimilar competition begins |
| 2027 |
USD 70,000 |
Patent expiry approaches, biosimilars entering market |
| 2030 |
USD 50,000 - 60,000 |
Market stabilization with biosimilars and generics |
Strategic Considerations
- Market share gains: Expansion into early-stage treatment could enable volume growth, potentially offsetting price declines.
- Cost management: Manufacturers may need to reduce manufacturing costs to sustain margins amid price erosion.
- Competitive positioning: Emphasizing efficacy, safety profile, and label expansion supports premium pricing longer term.
Key Takeaways
- NDC 70792-0812 (Kadcyla) commands high list prices, with negotiated prices typically lower.
- Sales are driven by metastatic and adjuvant indications; expansion to earlier stages could boost volume.
- Patent expiration around 2028-2029 likely will reduce prices significantly via biosimilar entry.
- The market dynamic shifts toward biosimilars and value-based reimbursement models.
- Price erosion is expected to accelerate over the next five years, with treatment cycle prices decreasing by approximately 50% by 2030.
FAQs
1. How does the patent expiry affect Kadcyla's pricing?
Patent expiry allows biosimilar entry, increasing competition and driving prices downward, likely halving prices by 2030.
2. Are biosimilars approved for Kadcyla?
As of 2023, biosimilars are under development; no biosimilar is yet approved, but approval is expected post-patent expiry.
3. What is the growth forecast for Kadcyla sales?
Annual revenue growth is estimated at 5-8% until 2025, driven by expanded indications; growth may plateau or decline post-patent expiry.
4. How does competition affect market share?
Emerging ADCs and biosimilars challenge Kadcyla's market dominance, potentially reducing market share from current levels.
5. What reimbursement strategies influence pricing?
Negotiated prices with payers and hospitals significantly impact actual treatment cycle costs, especially in major markets like the US, EU, and Japan.
References
- IQVIA. (2022). Global Oncology Market Data.
- U.S. Food and Drug Administration. (2013). Kadcyla approval information.
- EvaluatePharma. (2022). Oncology market forecasts.
- Biosimilar development pipeline. (2023). Biosimilar Market Overview.
- European Medicines Agency. (2022). Kadcyla (trastuzumab emtansine) summary of product characteristics.
